Development of RR in the JSTCT training set
| At treatment . | At day 28 . | n (%) . | 6-Month NRM (95% CI), % . | Day 28 RR∗ . |
|---|---|---|---|---|
| Grade 2 | Grade 0 | 1071 (45.7) | 5.9 (4.6-7.5) | Response |
| Grade 2 | Grade 1 | 263 (11.2) | 8.2 (5.2-11.9) | Response |
| Grade 2 | Grade 2 | 188 (8.0) | 23.4 (17.5-29.8) | Nonresponse |
| Grade 2 | Grade 3/4 | 39 (1.7) | 67.4 (49.5-80.1) | Nonresponse |
| Grade 2 | Second-line Tx | 128 (5.5) | 31.3 (23.3-39.6) | Nonresponse |
| Grade 3/4 | Grade 0 | 234 (10.0) | 8.3 (5.2-12.4) | Response |
| Grade 3/4 | Grade 1 | 41 (1.8) | 9.8 (3.0-21.2) | Response |
| Grade 3/4 | Grade 2 | 99 (4.2) | 34.5 (25.1-44.0) | Nonresponse |
| Grade 3/4 | Grade 3/4 | 99 (4.2) | 47.6 (37.4-57.1) | Nonresponse |
| Grade 3/4 | Second-line Tx | 179 (7.7) | 45.5 (38.0-52.7) | Nonresponse |
| At treatment . | At day 28 . | n (%) . | 6-Month NRM (95% CI), % . | Day 28 RR∗ . |
|---|---|---|---|---|
| Grade 2 | Grade 0 | 1071 (45.7) | 5.9 (4.6-7.5) | Response |
| Grade 2 | Grade 1 | 263 (11.2) | 8.2 (5.2-11.9) | Response |
| Grade 2 | Grade 2 | 188 (8.0) | 23.4 (17.5-29.8) | Nonresponse |
| Grade 2 | Grade 3/4 | 39 (1.7) | 67.4 (49.5-80.1) | Nonresponse |
| Grade 2 | Second-line Tx | 128 (5.5) | 31.3 (23.3-39.6) | Nonresponse |
| Grade 3/4 | Grade 0 | 234 (10.0) | 8.3 (5.2-12.4) | Response |
| Grade 3/4 | Grade 1 | 41 (1.8) | 9.8 (3.0-21.2) | Response |
| Grade 3/4 | Grade 2 | 99 (4.2) | 34.5 (25.1-44.0) | Nonresponse |
| Grade 3/4 | Grade 3/4 | 99 (4.2) | 47.6 (37.4-57.1) | Nonresponse |
| Grade 3/4 | Second-line Tx | 179 (7.7) | 45.5 (38.0-52.7) | Nonresponse |
The training set included 2341 patients.
Categorized by CART analyses based on 6-month NRM.